{"id":2963,"date":"2026-09-08T08:35:00","date_gmt":"2026-09-08T12:35:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2963"},"modified":"2026-09-08T20:40:27","modified_gmt":"2026-09-09T00:40:27","slug":"del-desiran-misses-phase-iii-harbor-primary-endpoint","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2963","title":{"rendered":"Del-desiran Misses Phase III HARBOR Primary Endpoint"},"content":{"rendered":"

Evidence<\/strong> Company ad hoc announcement · Discovery<\/strong> September 8, 2026 · Importance<\/strong> 5\/5 · Direction<\/strong> Negative<\/p>\n

\"Del-desiran<\/p>\n

Summary<\/h4>\n

Novartis disclosed that Phase III HARBOR did not show a statistically significant improvement versus placebo on video hand opening time, the primary endpoint in myotonic dystrophy type 1. The company reported evidence of activity in secondary and exploratory endpoints and described safety as generally consistent with prior data, but released no effect size, confidence interval, multiplicity hierarchy, subgroup, discontinuation or detailed safety results. Novartis is analyzing the dataset and will consult regulators before deciding the development path.<\/p>\n

What Happened<\/h4>\n

HARBOR randomized 159 participants to intravenous delpacibart etedesiran, or del-desiran, versus placebo every eight weeks for seven doses across a 54-week treatment period. Del-desiran is an antibody-oligonucleotide conjugate acquired with Avidity Biosciences; its transferrin-receptor-1-targeting antibody is intended to deliver an siRNA to skeletal muscle and reduce toxic DMPK RNA containing expanded CUG repeats. The primary video hand opening time endpoint is a novel digital measure of myotonia.<\/p>\n

The failed primary endpoint blocks a straightforward confirmatory interpretation. Positive secondary or exploratory results could reflect genuine domain-specific benefit, an insensitive primary measure, chance under multiple testing or imbalance in a small heterogeneous population. Without the full prespecified hierarchy, it is not possible to determine whether any secondary finding supports regulatory action. No approved disease-modifying treatment exists for DM1.<\/p>\n

Deep Analysis<\/h4>\n

The endpoint failed more than the mechanism:<\/strong> DM1 is multisystemic, variable and difficult to capture with a single hand-myotonia measure. Evidence across other functional outcomes could reveal benefit missed by vHOT, and prior studies supported target engagement. A pivotal trial is designed around its chosen endpoint; failure weakens the causal case and secondary patterns can be distorted by multiplicity, missing data and selective emphasis.<\/p>\n

Muscle RNA correction may be insufficient for meaningful function:<\/strong> Reducing toxic DMPK RNA in skeletal muscle may not reverse established muscle architecture, central nervous system effects, cardiac disease or other manifestations over 54 weeks. The negative endpoint may therefore expose a limitation of tissue reach or disease reversibility. Novartis’s other AOC programs target different transcripts, diseases and outcome measures, so HARBOR does not invalidate antibody-oligonucleotide delivery as a platform.<\/p>\n

Signal Extraction<\/h4>\n

Verified facts: randomized Phase III primary endpoint missed; 159 participants; seven infusions over 54 weeks; secondary and exploratory activity claimed; full analysis and regulatory consultation pending. Missing facts: primary effect size, statistical plan, exact secondary outcomes, subgroup consistency, target engagement by exposure, deaths, serious adverse events and open-label-extension status. Downgrade evidence would be weak or inconsistent secondary effects, safety imbalance or discontinuation.<\/p>\n

Company and Product Background<\/h4>\n

Novartis acquired del-desiran through its purchase of Avidity Biosciences. The molecule couples an antibody targeting transferrin receptor 1 with an siRNA against DMPK messenger RNA, seeking uptake into skeletal muscle. In DM1, expanded CTG repeats in DMPK generate toxic RNA that traps RNA-binding proteins and disrupts splicing across many genes, producing myotonia, weakness and systemic disease. The approach is intended to lower the toxic transcript while preserving delivery to muscle.<\/p>\n

DM1 development includes oligonucleotides, small molecules and genetic strategies, but no approved disease-modifying therapy. HARBOR raises the evidence threshold for digital hand-function endpoints and for linking molecular correction to meaningful function. The result follows separate Novartis setbacks in pelacarsen and autoimmune cell therapy, but no inference about company-wide financial condition or management motive is warranted from temporal clustering. Other AOC assets have distinct targets and should be judged on their own data.<\/p>\n

InSilens Take<\/h4>\n

HARBOR is a negative clinical signal because the pivotal primary endpoint failed, independent of the asset’s strategic history or acquisition price. It is not yet a clean mechanism verdict: DM1 measurement and tissue biology provide plausible alternatives, and no detailed dataset is public. The burden now shifts to Novartis to show that any secondary effect is prespecified, statistically credible, clinically meaningful and supported by molecular pharmacology. Until then, development optionality should not be confused with a viable regulatory path.<\/p>\n

Signal Assessment<\/h4>\n\n\n\n\n\n
Signal Importance<\/strong><\/td>\n5 \/ 5 — a pivotal failure affects a leading DM1 program and the clinical validation of targeted oligonucleotide delivery to muscle<\/td>\n<\/tr>\n
Signal Direction<\/strong><\/td>\nNegative — the prespecified primary endpoint was not met<\/td>\n<\/tr>\n
Confidence in Facts<\/strong><\/td>\nHigh — disclosed in a same-day company ad hoc announcement; trial design is registered<\/td>\n<\/tr>\n
Confidence in Interpretation<\/strong><\/td>\nModerate — secondary results, pharmacology and complete safety are not yet available, limiting asset- and platform-level conclusions<\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Novartis disclosed that Phase III HARBOR did not show a statistically significant improvement versus placebo on video hand opening time, the primary endpoint in myotonic dystrophy type 1. The company reported evidence of activity…<\/p>\n","protected":false},"author":1,"featured_media":2973,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[617,615,618,616],"class_list":["post-2963","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-avidity-biosciences","tag-del-desiran","tag-dmpk","tag-myotonic-dystrophy-type-1"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2963","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2963"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2963\/revisions"}],"predecessor-version":[{"id":2994,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2963\/revisions\/2994"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2973"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2963"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2963"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2963"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}